Hudson Bay Capital Management LP Boosts Stock Position in Genmab A/S (NASDAQ:GMAB)

Hudson Bay Capital Management LP grew its position in shares of Genmab A/S (NASDAQ:GMAB) by 103.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 540,000 shares of the company’s stock after acquiring an additional 275,000 shares during the period. Hudson Bay Capital Management LP’s holdings in Genmab A/S were worth $11,270,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. EverSource Wealth Advisors LLC boosted its stake in Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after buying an additional 939 shares in the last quarter. Lindbrook Capital LLC lifted its holdings in shares of Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after acquiring an additional 950 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after acquiring an additional 1,051 shares during the last quarter. Barclays PLC boosted its stake in shares of Genmab A/S by 1,072.8% in the 4th quarter. Barclays PLC now owns 2,498 shares of the company’s stock valued at $52,000 after purchasing an additional 2,285 shares in the last quarter. Finally, Cromwell Holdings LLC grew its holdings in shares of Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock valued at $60,000 after purchasing an additional 2,496 shares during the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Stock Down 0.2%

Shares of Genmab A/S stock opened at $19.39 on Monday. The business has a 50 day moving average of $20.07 and a 200 day moving average of $20.86. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $30.41. The company has a market cap of $12.43 billion, a PE ratio of 11.14, a P/E/G ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.26 by $0.05. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, research analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on GMAB. William Blair upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th. Truist Financial lowered their target price on Genmab A/S from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. BNP Paribas upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. HC Wainwright restated a “buy” rating and set a $37.00 price target (down from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. Finally, Leerink Partners upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a research report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $39.17.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.